Long COVID, a condition that occurs when patients still have symptoms at least three months after clearing infection, has been well-documented in adults, but its impact on children has been less clear.
A large study of Veterans Affairs (VA) patients in JAMA Internal Medicine shows that, during the 2022 to 2023 season, having COVID-19 was associated with more severe disease outcomes than flu or respiratory syncytial virus (RSV) infection. Differences became less pronounced, however, during the 2023 to 2024 season.
Using current estimates of US long-COVID burden (assuming the probability of long COVID is 6% and symptoms last 1 year), cases cost an average of $2.01 billion annually. The economic burden of long COVID already surpasses that of carpal tunnel, Lyme disease, and psoriasis, the authors said, and is likely to continue to grow.